Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has received a consensus rating of “Hold” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $40.00.
RHHBY has been the subject of a number of recent research reports. Argus restated a “hold” rating on shares of Roche in a report on Monday, March 4th. Morgan Stanley lowered shares of Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th.
View Our Latest Research Report on Roche
Institutional Inflows and Outflows
Roche Stock Down 2.2 %
Shares of RHHBY opened at $30.54 on Thursday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35. Roche has a fifty-two week low of $29.95 and a fifty-two week high of $40.48. The firm has a 50 day moving average price of $31.99 and a 200-day moving average price of $33.68.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Read More
- Five stocks we like better than Roche
- Want to Profit on the Downtrend? Downtrends, Explained.
- High-Yield Texas Instruments Could Hit New Highs Soon
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How Technical Indicators Can Help You Find Oversold Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.